Views

CrossRef citations to date

Altmetric

Original Article

BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma

Yoshikazu ItoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan; Correspondence[email protected]

Tomohiro UmezuInstitute of Medical Science, Tokyo Medical University, Shinjuku-ku, Japan;

Kenichi TadokoroDevelopment of Clinical Genomics, BML, Inc, Saitama, Japan;

Yuu SaitoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Seiichiro KatagiriDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Tamiko SuguroDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Michiyo AsanoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Seiichiro YoshizawaDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Daigo AkahaneDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Yuko TanakaDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Hiroaki FujimotoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Seiichi OkabeDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Moritaka GotohDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Tetsuzo TauchiDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

Chiaki KawanaInstitute of Medical Science, Tokyo Medical University, Shinjuku-ku, Japan;

Junko H. OhyashikiInstitute of Medical Science, Tokyo Medical University, Shinjuku-ku, Japan;

Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Kanagawa, Japan

Kazuma OhyashikiDepartment of Hematology, Tokyo Medical University, Tokyo, Japan;

show all

Abstract

Deletion polymorphism of BCL-2-like protein 11 (BIM) is specifically found in East Asia. To explain some epidemiological discrepancies between Asian and Western countries, we analyzed a silent single nucleotide polymorphism (SNP) in exon 5 (c465C > T) and a deletion site (2903 bp) in intron 2 in 77 patients with follicular lymphoma by the Q-invader method using PCR. In females, 5-year progression-free survivals (PFS) were 20.0% in the BIM deletion group, 66.7% in the SNP group and 81.5% in the wild-type (WT) group (p = .0012). In the WT group, 5-year PFS was 40.4% in males (p = .0448 vs. female PFS). This tendency was strengthened in patients receiving rituximab (26.9% vs. 84.2%, p = .006). Superior PFS in the WT females in Japan was comparable with the results of cohort studies in the United States and Sweden. Favorable prognosis in Japanese females may be masked by the BIM deletion polymorphism.

Keywords:

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1529310.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma

Information for

Open access

Opportunities

Help and information

BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma

Abstract

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature